You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

high-risk acute promyelocytic leukemia (APL/AML M3)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)

Recruiting
  • Acute Promyelocytic Leukemia
  • +2 more
  • Beijing, Beijing, China
    Peking University Institute of Hematology
Apr 26, 2023

Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL Trial in Dresden (observational)

Recruiting
  • Newly-diagnosed APL (de Novo or Therapy-related)
  • Relapsed APL
  • observational
  • Dresden, Germany
    Prof. Dr. U. Platzbecker
Aug 10, 2022

Acute Promyelocytic Leukemia Trial in Xi'an (Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide)

Recruiting
  • Acute Promyelocytic Leukemia
  • Realgar-Indigo naturalis formula
  • +3 more
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xi'an Jiaotong University
Aug 31, 2021

Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

Recruiting
  • Leukemia, Myeloid, Acute
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Dec 27, 2022

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker

Completed
Has Results
  • Alkylating Agent-Related Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 18, 2022

Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Vienna, Austria
  • +3 more
Jun 8, 2023

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

Acute Myelogenous Leukemia Trial in Rochester (Decitabine)

Completed
Has Results
  • Acute Myelogenous Leukemia
  • Rochester, New York
    University of Rochester
Jul 1, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Leukemia Trial in Tianjin (DNR:, Ara-c)

Completed
Has Results
  • Leukemia
  • Tianjin, Tianjin, China
  • +1 more
Aug 8, 2021

Haploidentical Stem Cell Transplantation, Conditioning Trial in Xi'an (MA-BUCY2, BUCY2)

Not yet recruiting
  • Haploidentical Stem Cell Transplantation
  • Conditioning
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Apr 14, 2023

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • +15 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Chicago, Illinois
  • +2 more
Jan 12, 2023

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Acute Myeloid Leukemia (AML) in Remission Trial in Suzhou (Azacitidine, Venetoclax, Supportive care)

Recruiting
  • Acute Myeloid Leukemia (AML) in Remission
  • Suzhou, Jiangsu, China
  • +1 more
Aug 18, 2022

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia Trial in United States

Recruiting
  • Relapsed Adult AML
  • +2 more
  • Specialty Palliative Care
  • Primary Palliative Care
  • Boston, Massachusetts
  • +3 more
Aug 12, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +3 more
  • Laboratory Biomarker Analysis
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Jan 10, 2022

Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial

Completed
  • Relapsed Acute Myeloid Leukemia (AML)
  • +2 more
  • Atlanta, Georgia
  • +5 more
Apr 4, 2022